Table 3 Levels of activities and/or proteins associated to HDL of controls and BC patients
From: High density lipoproteins and oxidative stress in breast cancer
| Â | Control | BC patients | Reference |
|---|---|---|---|
Serum paraoxonase (PON, U/mL) | 124.89 ± 21.70 | 42.99 ± 7.98 | [55] |
158.39 ± 23.04 | 96.44 ± 21 | [92] | |
Serum arylesterase (ARE) (U/mL) | 98.55 ± 18.82 | 54.51 ± 11.57 | [55] |
239.33 ± 32.98 | 159.75 ± 15.75 | [92] | |
Plasma paraoxonase (PON)(U/mL) | 95.00 ± 30.38 | 58.50 ± 1.67 | [93] |
Plasma arylesterase (ARE) (U/mL) | 52.10 ± 11.98 | 65.00 ± 28.29 | |
PON levels (μg/mL) | 80.62 ± 02.56 | 58.50 ± 1.67 | |
PON1 activity (U/L) | 274.3 (156.8–565.9) | 154.9 (99.9–260.2) | [92] |
PON1 concentration (mg/L) | 97.3 (43.2–285.3) | 91.7 (30.6–223.3) | |
Plasma LCAT (pg/ml) | 5.98 ± 0.88 | 5.12 ± 0.58 | [94] |
Plasma PLA2 activity | 1600 ± 100 | 1800 ± 100 | [95] |